Auris Medical (NASDAQ:EARS) announced its quarterly earnings data on Tuesday, November 28th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.20) by $0.06, Briefing.com reports.
Auris Medical (EARS) traded down $0.01 during midday trading on Thursday, reaching $0.39. 354,111 shares of the company’s stock traded hands, compared to its average volume of 479,755. The company has a debt-to-equity ratio of -14.04, a quick ratio of 1.86 and a current ratio of 1.86. Auris Medical has a fifty-two week low of $0.38 and a fifty-two week high of $1.50.
Separately, Zacks Investment Research raised shares of Auris Medical from a “hold” rating to a “buy” rating and set a $0.75 price objective for the company in a research note on Wednesday, August 30th.
ILLEGAL ACTIVITY NOTICE: “Auris Medical (NASDAQ:EARS) Posts Earnings Results, Beats Expectations By $0.06 EPS” was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece on another publication, it was copied illegally and republished in violation of US and international trademark & copyright legislation. The original version of this piece can be read at https://www.dispatchtribunal.com/2017/12/07/auris-medical-ears-posts-earnings-results-beats-estimates-by-0-06-eps.html.
Auris Medical Company Profile
Auris Medical Holding AG is a holding and clinical-stage biopharmaceutical company focused on the development of products for the treatment of inner ear disorders. Its advanced product candidate, AM-101, is in Phase III clinical development for acute inner ear tinnitus under a special protocol assessment (SPA) from the United States Food and Drug Administration.
Receive News & Ratings for Auris Medical Holding AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Auris Medical Holding AG and related companies with MarketBeat.com's FREE daily email newsletter.